- eXmoor Pharma and Siam Bioscience have formed a strategic partnership to establish a cell and gene therapy (CGT) development and manufacturing centre in Bangkok.
- The new centre will offer consultancy, process and analytical development, and GMP clinical and commercial manufacturing to support CGT programmes in Thailand and Southeast Asia.
eXmoor Pharma, an integrated cell and gene therapy CDMO with embedded consultancy expertise, has partnered with Siam Bioscience, a biopharmaceutical company in ASEAN, to develop a CGT centre in Bangkok. The collaboration aims to accelerate the growth of the CGT industry in Thailand and across Southeast Asia, providing comprehensive services to support local innovation and attract international therapies and investment.
The new centre will operate at Siam Bioscience’s manufacturing site, combining the companies’ expertise and infrastructure. Services will cover consultancy, process and analytical development, and GMP-compliant clinical and commercial manufacturing, supporting therapy developers working to deliver advanced medicines efficiently and in regulatory compliance.
“By combining Siam Bioscience’s regional leadership with eXmoor’s technical expertise and global CDMO capabilities, we are creating a launchpad to support both local breakthroughs and international partnerships. This is about bringing life-changing therapies to more patients, more quickly, and with the right infrastructure to support long-term success.”
Angela Osborne, Executive Chair of eXmoor Pharma
The partnership also seeks to introduce international CGTs and technologies into the region, improving patient access and strengthening sustainable healthcare systems. By offering a regionally based but globally aligned manufacturing model, the collaboration aims to reduce delays, lower logistic burdens, and improve equity of access to transformative therapies.
